Enhanced Protection against Ebola Virus Mediated by an Improved Adenovirus-Based Vaccine
MetadataShow full item record
Background -- The Ebola virus is transmitted by direct contact with bodily fluids of infected individuals, eliciting death rates as high as 90% among infected humans. Currently, replication defective adenovirus-based Ebola vaccine is being studied in a phase I clinical trial. Another Ebola vaccine, based on an attenuated vesicular stomatitis virus has shown efficacy in post-exposure treatment of nonhuman primates to Ebola infection. In this report, we modified the common recombinant adenovirus serotype 5-based Ebola vaccine expressing the wild-type ZEBOV glycoprotein sequence from a CMV promoter (Ad-CMVZGP). The immune response elicited by this improved expression cassette vector (Ad-CAGoptZGP) and its ability to afford protection against lethal ZEBOV challenge in mice was compared to the standard Ad-CMVZGP vector. Methodology/Principal Findings -- Ad-CMVZGP was previously shown to protect mice, guinea pigs and nonhuman primates from an otherwise lethal challenge of Zaire ebolavirus. The antigenic expression cassette of this vector was improved through codon optimization, inclusion of a consensus Kozak sequence and reconfiguration of a CAG promoter (Ad-CAGoptZGP). Expression of GP from Ad-CAGoptZGP was substantially higher than from Ad-CMVZGP. Ad-CAGoptZGP significantly improved T and B cell responses at doses 10 to 100-fold lower than that needed with Ad-CMVZGP. Additionally, Ad-CAGoptZGP afforded full protections in mice against lethal challenge at a dose 100 times lower than the dose required for Ad-CMVZGP. Finally, Ad-CAGoptZGP induced full protection to mice when given 30 minutes post-challenge. Conclusions/Significance -- We describe an improved adenovirus-based Ebola vaccine capable of affording post-exposure protection against lethal challenge in mice. The molecular modifications of the new improved vaccine also translated in the induction of significantly enhanced immune responses and complete protection at a dose 100 times lower than with the previous generation adenovirus-based Ebola vaccine. Understanding and improving the molecular components of adenovirus-based vaccines can produce potent, optimized product, useful for vaccination and post-exposure therapy.
Jason S. Richardson is with the Public Health Agency of Canada, Michel K. Yao is with the Public Health Agency of Canada, Kaylie N. Tran is with the Public Health Agency of Canada and University of Manitoba, Maria A. Croyle is with UT Austin, James E. Strong is with the Public Health Agency of Canada and University of Manitoba, Heinz Feldmann is with the Public Health Agency of Canada and University of Manitoba, Gary P. Kobinger is with the Public Health Agency of Canada and University of Manitoba.
CitationRichardson JS, Yao MK, Tran KN, Croyle MA, Strong JE, et al. (2009) Enhanced Protection against Ebola Virus Mediated by an Improved Adenovirus-Based Vaccine. PLoS ONE 4(4): e5308. doi:10.1371/journal.pone.0005308
The following license files are associated with this item:
Showing items related by title, author, creator and subject.
Haelle, Tara Susan (2012-05)The invention of the vaccine has been one of the greatest public health triumphs of the modern world. Each new vaccine has saved thousands - even millions - of lives worldwide, but this success has been fraught with ...
The potently neutralizing monoclonal antibody 1B7 : its unique epitope, effects on intracellular trafficking, and elicitation upon infection with pertussis Sutherland, Jamie Nicole (2010-08)Disease caused by Bordetella pertussis persists with rates increasing over the past decade in industrialized countries. A hindrance to vaccine development has been the lack of a clear serological correlate of protective ...
Economic evaluation of using adenovirus type 4 and type 7 vaccines in United States military basic trainees Vazquez, Meredith Hodges (2014-05)Adenoviruses, particularly types 4 and 7, are associated with febrile respiratory illness (FRI) outbreaks in US military basic trainees. Vaccines against these two serotypes controlled FRI in basic trainees until production ...